Genetron Health to Present at Canaccord Genuity 40th Annual Growth Conference

Rhea-AI Summary

Genetron Holdings Limited (NASDAQ:GTH) announced participation in the Canaccord Genuity 40th Annual Growth Conference, scheduled virtually from August 11-13, 2020. On August 13, management will conduct a fireside chat at 8:00 am ET and a panel discussion at 11:00 am ET focused on cancer screening technologies. The event will be accessible via webcast, with recordings available for 30 days afterward. Genetron is a leading precision oncology platform in China, specializing in molecular profiling tests for cancer management.

BEIJING, July 29, 2020 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, today announced that management will present and host one-on-one meetings at the Canaccord Genuity 40th Annual Growth Conference to be held virtually on August 11-13, 2020.

On Thursday, August 13^th, the Genetron management will participate in the following:

• Fireside chat at 8:00 am ET (8:00 pm Beijing time) with Sizhen Wang, Chief Executive Officer
• Panel discussion entitled, “Cancer screening for asymptomatic individuals. Single vs. multi-target testing; different technological approaches; and opportunities/challenges to drive broad-based adoption,” at 11:00 am ET (11:00 pm Beijing Time) with Yun-Fu Hu, PhD, Chief Medical Officer

A webcast of the presentation will be available on the "News and Events" page of the Investors section of the Company's website. A replay of each webcast will be available for 30 days following the event. For more information, please visit https://ir.genetronhealth.com/investors.

About Genetron Holdings Limited

Genetron Holdings Limited (“Genetron Health” or the “Company”) is a leading precision oncology platform company in China that specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment. The Company has developed a comprehensive oncology portfolio that covers the entire spectrum of cancer management, addressing needs and challenges from early screening, diagnosis and treatment recommendations, as well as continuous disease monitoring and care. Genetron also partners with global biopharmaceutical companies and offers customized services and products. For more information, please visit ir.genetronhealth.com.

Safe Harbor Statement

This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Company’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a number of factors could cause actual results to differ materially from those contained in any forward-looking statement. In some cases, forward-looking statements can be identified by words or phrases such as “may”, “will,” “expect,” “anticipate,” “target,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the SEC. All information provided in this press release is as of the date of this press release, and the Company does not undertake any duty to update such information, except as required under applicable law.

Investor Relations Contacts
US:
Hoki Luk
Head of Investor Relations
Email: hoki.luk@genetronhealth.com
Phone: +1 (408) 204-5343

Stephanie Carrington
Westwicke, an ICR Company
Email: Stephanie.Carrington@westwicke.com
Phone: +1 (646) 277-1282

Asia:
Bill Zima
ICR, Inc.
Email: bill.zima@icrinc.com
GenetronIR@icrinc.com

Media Relations Contact
Edmond Lococo
ICR
Edmond.Lococo@icrinc.com
Mobile: +86 138-1079-1408
genetron.pr@icrinc.com

FAQ

What is Genetron Holdings Limited presenting at the Canaccord Genuity 40th Annual Growth Conference?

Genetron Holdings Limited will present a fireside chat and participate in a panel discussion on cancer screening on August 13, 2020.

When will Genetron's fireside chat take place during the conference?

The fireside chat featuring Genetron's CEO will occur at 8:00 am ET on August 13, 2020.

What topics will be discussed in Genetron's panel discussion at the conference?

The panel discussion will cover 'Cancer screening for asymptomatic individuals. Single vs. multi-target testing; different technological approaches; and opportunities/challenges to drive broad-based adoption.'

Is the Canaccord Genuity conference open to the public?

Yes, the presentation will be available via webcast to the public, with replays accessible for 30 days.

What is the focus of Genetron Holdings Limited?

Genetron specializes in precision oncology, offering molecular profiling tests to enhance cancer treatment and management.